Onc File published (year): 2022

CEO of Oncoinvent, Jan A. Alfheim, will be presenting the company at the 4th Targeted Radiopharmaceuticals Europe December 7 at 14:30

CFO of Oncoinvent, Tore Kvam, will be presenting the company at Carnegie Nordic Life Science Champions Seminar December 7 at 14:30

CEO of Oncoinvent, Jan A. Alfheim, will be presenting the company at ABGSC Norwegian Oncology Seminar November 23 at 12:50

The aim of this study was to estimate the absorbed doses to normal tissues for patients injected intraperitoneally with a suspension of radium-224 adsorbed in calcium carbonate microparticles (224Ra-CaCO3-MP) for treating peritoneal carcinomatosis originating from colorectal cancer.

CEO, Jan A. Alfheim, will be speaking at the LSX Nordic Biotech Congress and host 1-on-1 meetings with investors on 6-7 September, 2022

First patient has been treated in the RAD-18-002 phase 2A clinical study

All dose levels of Radspherin® were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study.

Radspherin® is currently being evaluated in two ongoing Phase 1 trials for the treatment of peritoneal carcinomatosis from ovarian cancer and colorectal cancer

Oncoinvent would like to extend an invitation to a presentation of the Q1 2022 results. The presentation will be held on Wednesday 1. June 2022 at 08:30 AM in the offices of the company at Gullhaugsveien 7, Oslo, 3rd Floor. To attend, please register with kvam@oncoinvent.com. Oncoinvent ønsker med dette å invitere til presentasjon av … Read more

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

Largest shareholders

IR Contact

+47 22 18 33 05

Oncoinvent AS Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

+47 488 68 863

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close